从纤维细胞生长因子受体抑制剂的指甲毒性管理
Journal of drugs in dermatology : JDD
|March 4, 2026
概括
纤维细胞生长因子受体抑制剂 (FGFRi) 可以导致癌症患者的指甲毒性. 有管理策略可用,但预防和优化护理需要进一步的研究.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 皮肤病学 皮肤病学
背景情况:
- 纤维细胞生长因子受体 (FGFR) 信号改变与各种癌症有关.
- FGFR抑制剂 (FGFRi) 越来越多地用于治疗泌尿器癌,胆管癌和胃肠癌.
- 甲毒性 (例如,阴溶解,阴) 是FGFRi的一个未被认可的不良影响.
研究的目的:
- 系统地审查和描述FGFR抑制剂相关的指甲疾病.
- 分析FGFRi相关指甲毒性的发生率,严重程度,发病和管理.
- 确定FGFRi诱导的指甲并发症未来研究的需求.
主要方法:
- 对PubMed和谷歌的系统文献审查,截至2025年3月.
- 包括病例报告,试验和对FGFRi和指甲不良事件的回顾性研究.
- 提取有关发病率,严重程度 (CTCAE v5.0),发病,管理和治疗影响的数据;使用威尔科克森和奇方测试进行统计分析.
主要成果:
- 分析了23项涉及1561名患者的研究,540人经历了指甲毒性.
- 甲毒性率最高的是erdafitinib (43.3%),最低的是derazantinib (5.3%).
- 1-2级事件最常见;3级事件导致3/540名患者的剂量减少;没有报告停止治疗. 管理包括消毒剂浸泡,局部类固醇,口服抗生素和保护性指甲护理.
结论:
- 与FGFRi相关的指甲毒性因代理物而异,影响生活质量和治疗坚持.
- 对于FGFRi指甲毒性的致病性和预测生物标志物尚不清楚.
- 优化管理和预防策略需要进一步的研究;早期识别和多学科的护理是必不可少的.
相关概念视频
Accessory Structures of the Skin: Nails
3.8K
Nails are one of the important accessory structures of the skin. They are hard, protective structures that cover the dorsal surface of the distal phalanges of fingers and toes. Nails are composed of specialized keratinized cells and serve various functions, including protection, sensation, and manual dexterity.
The main components of a nail include the following.
Nail Plate: The nail plate is the visible portion of the nail that extends beyond the fingertips or toes. It is a hard, translucent...
The main components of a nail include the following.
Nail Plate: The nail plate is the visible portion of the nail that extends beyond the fingertips or toes. It is a hard, translucent...
3.8K
Drug toxicity: Drug–Drug Interaction
133
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
133
Peripheral Artery Disease IV: Nursing Management
506
The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
506
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
600
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
600
Drug Toxicity: Dose-Dependent Reactions
74
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
74

![Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F68356.jpg&w=3840&q=50)
